Our Vision

Our Business Model is built around a simple but compelling technical and clinical development proposition:

• Optimise the TrophiCell technology platform: Exploit the ability to generate large quantities of single source natural MSCs to optimise and standardise every stage of the production of TrophiCell based therapeutics, from donor selection though optimisation of potency and homing through to patient stratification, dosing and administration routes. Our contention is that “smart development” and the cumulative indication specific optimisation of every stage of production will lead to a step change improvement in clinical efficacy.
• Clinically validate the TrophiCell therapeutic modality in lead indications
• Partner with pharma when we have validated the efficacy of TrophiCell therapies in Phase I/IIa trials in the lead indications and can demonstrate a high probability of achieving a Target Product Profile that will confer clinical and economic advantage over the current best standard of care.

Our Clinical Strategy is to exemplify in lead indications where MSCs have shown the most promise in clinical trials and where there remains an unmet clinical need and compelling business case in terms of addressable market. Our two lead indications of osteoarthritis and late stage liver disease also represent high incidence debilitating pathology and lower incidence life limiting disease respectively. This demonstrates the potential to address diverse sectors of the healthcare market and underpins future expansion into the broader areas of unmet clinical need in inflammatory and fibrotic disease.